CD274 and non-small cell lung carcinoma: (2021) (72) evaluated the outcomes of smokers versus never-smokers with advanced NSCLC and high PD-L1 ≥ 50% treated with pembrolizumab monotherapy in the first line in a retrospective multicenter cohort of 962 patients.